ReviewBiomedical reports2026
Role of the gut microbiota in the pathogenesis and therapeutic approach to osteoporosis (Review).
Review in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Gut-Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health.Life (Basel, Switzerland) · 2026Review
- Berberine Attenuates Glucocorticoid-Induced Bone Loss in Mice: Associated with the Gut Microbiota-Glycerophospholipid Metabolic Axis.Foods (Basel, Switzerland) · 2026Article
- The role of gut microbiota-immune-endocrine crosstalk in the pathogenesis of osteoporosis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is a chronic systemic metabolic bone disease characterized by an imbalance between bone resorption and bone formation, resulting in a decrease in bone mass and density. Additionally, the deterioration of bone tissue microstructure increases the risk of fracture. This condition not only impairs the quality of life of patients but also threatens their safety. With the gradual aging of the population of China, the incidence of OP has been increasing annually, becoming a major public health issue threatening the health of middle-aged and elderly individuals, particularly women in these age groups. OP has garnered increasing attention due to its high prevalence and severe complications. OP has many triggering factors and a complex pathogenesis, which are currently considered to be related to hormones, the endocrine and immune systems, and gut microbiota (GM). With the continuous development of modern medical research, the association between GM and OP has emerged as a hotspot in the field of orthopedics in recent years. Current evidence confirms that GM can influence systemic regulation through various metabolic pathways, either directly or indirectly, employing a multi-channel, multi-target effect on both preventing and controlling OP. However, current research still faces limitations such as the homogeneity of animal models, insufficient investigation of multi-pathway interactions, and inadequate clinical translational evidence. Future studies should leverage multi-omics technologies to elucidate the GM-bone axis mechanisms in depth, thereby advancing the clinical application of traditional Chinese medicine (TCM) in the prevention and treatment of OP. The present review summarizes the associations between GM and the development of OP, as well as the application of TCM, probiotics and prebiotics in regulating GM for OP management, aiming to provide novel therapeutic strategies for its clinical prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.